Transforming Growth Factor-beta and Ciliary Neurotrophic Factor Synergistically Induce Vasoactive Intestinal Peptide Gene Expression through the Cooperation of Smad, STAT, and AP-1 Sites*

Richard L. Pitts, Shuibang Wang, Elizabeth A. Jones, and Aviva J. SymesDagger

From the Department of Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814

Received for publication, December 28, 2001, and in revised form, February 20, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The cytokine ciliary neurotrophic factor (CNTF) and transforming growth factor-beta (TGF-beta ) both induce transcription of the vasoactive intestinal peptide (VIP) gene through a 180-base pair cytokine response element (CyRE) in the VIP promoter. While CNTF induces STAT and AP-1 proteins to bind to cognate sites in the VIP CyRE, the mechanism through which TGF-beta acts to induce VIP gene transcription is not known. Here we show that Smad3 and Smad4 proteins can bind to two distinct sites within the VIP CyRE. These sites are absolutely required for the induction of VIP CyRE transcription by TGF-beta . TGF-beta induces endogenous Smad-containing complexes to bind to these sites in human neuroblastoma cells. CNTF and TGF-beta synergize to induce VIP mRNA expression and transcription through the VIP CyRE. This synergy is dependent on the Smad, STAT, and AP-1 sites, suggesting that these two independent cytokine pathways synergize through the cooperation of pathway-specific transcription factors binding to distinct sites within the VIP CyRE.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Transforming growth factor-beta (TGF-beta )1 and ciliary neurotrophic factor (CNTF) have many functions in the developing and mature nervous system. These two unrelated cytokines mediate their effects through separate and distinct signaling cascades. CNTF, a member of the gp130 cytokine family, utilizes a multimeric receptor structure consisting of a GPI-linked ligand binding subunit, CNTFR-alpha , and two related transmembrane signal-transducing subunits, gp130 and leukemia inhibitory factor (LIF) receptor-beta (1-4). Neither of these transmembrane components have intrinsic kinase activity; instead, they associate with the Jak/Tyk tyrosine kinases (5-7). Activation of these kinases by ligand-induced receptor multimerization is thought to initiate signal transduction and activation of gene expression (5, 8, 9). Cytokine stimulation induces STAT proteins to "dock" onto the receptor, enabling their own tyrosine phosphorylation (8, 10-12). Subsequently, STAT proteins translocate to the nucleus and bind to STAT sites in regulated genes to provide a rapid means of activating gene transcription (reviewed in Ref. 13). Various other signaling moieties are also activated by CNTF including the Ras-mitogen-activated protein kinase pathway (14-17), SHP-2 tyrosine phosphatase (18), phosphatidylinositol 3-kinase (15, 19), and components of the AP-1 transcription factor family (20, 21).

TGF-beta signals through TGF-beta type I (Tbeta R-I) and type II receptors (Tbeta R-II), which possess intrinsic serine-threonine kinase activity (for reviews of TGF-beta signal transduction, see Refs. 22 and 23). The TGF-beta ·Tbeta R-II complex recruits and then phosphorylates Tbeta R-I to initiate signaling. The activated Tbeta R-I phosphorylates the receptor-regulated Smad proteins, Smad2 and Smad3. Phosphorylated Smads dissociate from the receptor, complex with the co-Smad Smad4, and translocate to the nucleus. Smads bind to specific Smad sites in genomic regulatory regions. However, their DNA binding affinity is weak (24), and they usually complex with other classes of transcription factor to establish strong DNA binding to induce gene transcription of regulated genes (25).

Despite their differences, TGF-beta and CNTF share some functional similarity. Both cytokines have neurotrophic actions, enhancing the survival of various populations of neurons in the central and peripheral nervous system (26-32). In addition, TGF-beta enhances CNTF-mediated survival of cultured ciliary neurons, suggesting that TGF-beta may act together with CNTF in specific cell populations (33). While these two cytokines sometimes share similar functions, the mechanism through which they may cooperate has not been investigated. We have previously shown that CNTF and activin, a TGF-beta -related cytokine, independently induce VIP gene expression through a 180-bp element in the VIP promoter termed the cytokine response element (CyRE) (34). CNTF induces VIP gene expression through the induction of STAT and AP-1 proteins to bind to distinct sites within the CyRE (20, 35). These cytokine-induced proteins interact with other noninduced proteins to bring about a robust activation of VIP transcription through combinatorial interactions (36). While CNTF induces VIP gene expression ~50-fold, activin has a smaller effect on VIP mRNA, inducing it ~2-fold (34). However, co-treatment of CNTF and activin leads to a synergistic activation of VIP transcription mediated through the VIP CyRE. TGF-beta also synergizes with CNTF to induce CyRE-directed transcription (34). However, TGF-beta does not induce either STAT or AP-1 proteins to bind to the CyRE (34), and we do not know the molecular mechanisms through which TGF-beta and related cytokines induce VIP gene expression. Understanding the TGF-beta -initiated signaling pathways that regulate the VIP gene will allow us to investigate the mechanisms through which these two independent cytokine signals synergize to regulate neuropeptide gene expression. In this paper, we show that there are two Smad binding sites within the CyRE, distinct from the AP-1 and STAT sites, that are critical to the TGF-beta regulation of VIP gene expression. We further show that the Smad, STAT, and AP-1 sites all contribute to the synergistic interaction between CNTF and TGF-beta in the induction of VIP gene expression.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Cell culture reagents were obtained from Mediatech (Herndon, VA), fetal bovine/horse serum from Life Technologies, Inc., and culture plates from Costar (Corning, NY). Recombinant human CNTF was a gift from Regeneron Pharmaceuticals (Tarrytown, NY), and TGF-beta was purchased from R & D Systems (Minneapolis, MN). Oligonucleotides were synthesized on a PE Applied Biosystems 394 synthesizer by the Uniformed Services University of the Health Sciences in-house oligonucleotide facility. Anti-Smad2/3 antiserum was obtained from Upstate Biotechnology, Inc. (Lake Placid, NY). The Gal4-Smad fusion plasmids, pG5-E1Bluc, and bacterial expression vectors for GST-Smad4 and GST-Smad3Delta C were obtained from Dr. R. Lechleider (Department of Pharmacology, Uniformed Services University of the Health Sciences) (37).

Plasmids-- Details of Cy1luc, the Cyluc deletion series, 3×G3 luc, and 3×G2 luc have all been described (35). The series of 3-bp substitution mutants of Cy1luc was amplified from Cy1luc as described previously (36). The plasmid Cy1mS5 is identical to Cy1 mg11luc. Cy1 mg17luc was constructed by polymerase chain reaction site-directed mutagenesis (38) with the oligonucleotides 5'-CAAC TGGGAAACAAATTTCCATCGATTTTGAAACTTAATTC-3' and 5'-GAATTAAGTTTCAAAATCGATGGAAATTTGTTTCCCAGTTG-3'. These oligonucleotides were paired, with either A1 or A4 (35), and Cy1luc as template to create new fragments. The fragments were gel-purified and used as template in a subsequent polymerase chain reaction with oligonucleotides A1 and A4 as primers to create Cy1mg17luc. This plasmid, Cy1mg17luc, was used as template with primers A1 and mS5 (36) to create Cy1mg17mg11. Cy1mg17mg11luc was then used as template DNA to construct the further mutated Cy1mG17mG11mG3luc, Cy1mG17mG11mG2luc, and Cy1mG17mG11mG3mG2luc using the CLONTECH Transformer site-directed mutagenesis kit (CLONTECH Inc. Palo Alto, CA). All plasmids were sequenced to confirm their identity. SBE-luc contained four copies of the Smad-binding element (SBE) consensus (39). The Gal4-Smad fusion plasmids, pG5-E1Bluc, and bacterial expression vectors for GST-Smad4 and GST-Smad3Delta C have been described previously (37).

Cell Culture and Transfection-- NBFL cells were maintained and transfected as described previously (40). Cells were plated at 1.5 × 105 cells/well in six-well plates and transfected overnight by calcium phosphate precipitation. Each well received 1 µg of luciferase reporter construct, 0.5 µg of EF-beta -galactosidase, and 2.5 µg of carrier DNA. Cytokines were added in serum-free medium, 6 h after the DNA precipitate was removed, for 40 h before cell harvesting. Samples were assayed for luciferase activity (41) and beta -galactosidase activity (Galacto-Light Plus kit, Tropix Inc, MA). Luciferase activity was normalized to beta -galactosidase activity to control for transfection efficiency.

RNA Isolation and Analysis-- Total cytoplasmic RNA was isolated from NBFL cells after lysis with Nonidet P-40 and transferred to nylon membranes as previously described (42). Northern blots were hybridized with a 580-bp HindIII/EcoRI fragment of human VIP cDNA (43) and rehybridized with a probe for the unregulated internal reference gene cyclophilin (44). Blots were digitized using a Storm PhosphorImager, with ImageQuant software (Molecular Dynamics, Inc., Sunnyvale, CA). The relative densitometric readings were normalized to cyclophilin mRNA to account for loading differences between lanes.

Electrophoretic Mobility Shift Assay (EMSA)-- EMSAs were performed as previously described (35). NBFL cells were grown to confluency and serum-starved overnight before treatment with TGF-beta for the times indicated. GST-Smad fusion proteins were prepared as described (37). Nuclear extracts were prepared, and binding reactions performed as previously described (35). Synthetic complementary oligonucleotides with GGG overhangs were annealed and labeled with [alpha -32P]dCTP using Moloney murine leukemia virus reverse transcriptase (Promega, WI). When used, competitor oligonucleotides or antibodies were incubated with the nuclear extracts for 10 min at room temperature prior to the addition of probe.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have previously shown that TGF-beta induction of VIP gene transcription is mediated through the VIP CyRE. To determine which regions within the 180-bp CyRE are important for the TGF-beta -mediated transcriptional induction, we transfected NBFL neuroblastoma cells with a series of CyRE deletion constructs. These plasmids contain various regions of the CyRE upstream of a basal RSV promoter driving expression of the luciferase reporter gene (35). As described previously, luciferase activity in cells transfected with the full-length Cy1luc was induced after treatment with TGF-beta ~4-fold (34). Deletion of 28 bp at the 3'-end of the CyRE either from the full-length construct or from two other plasmids with deleted 5'-ends reduced the transcriptional induction of CyRE luciferase reporter plasmids by over 60% (Fig. 1). However, deletion of up to 50 bp from the 5'-end of the CyRE did not significantly reduce the induction of luciferase activity driven by these plasmids in response to TGF-beta . These data suggest that a region within the most 3' 28 bp of the CyRE is important to the TGF-beta -mediated induction of VIP CyRE transcription.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 1.   Deletion of the 3' end reduces the TGF-beta inducibility of the CyRE. NBFL cells, transfected with the luciferase reporter plasmids shown, were either left untreated or treated for 40 h with TGF-beta (2.5 ng/ml) before harvesting and analysis of luciferase and beta -galactosidase activity. Data are presented as -fold induction of luciferase activity normalized to beta -galactosidase activity (mean ± S.E.) of three independent experiments.

To examine more precisely the sequences within this 3' region that contribute to the TGF-beta induction of VIP transcription, we transfected NBFL cells with CyRE-luciferase plasmids containing a sequential series of 3-bp mutations of the most 3' 30 bp (Fig. 2). TGF-beta was unable to induce transcriptional activity in cells transfected with either Cy1mS4luc or Cy1mS5luc (Fig. 2). These plasmids contain sequential mutations of the sequence GTCTGA, which, read inverted on the minus strand, contains a CAGA box (TCAGAC). In other promoters, this CAGA motif can bind Smad proteins and mediate TGF-beta induced transcription (39, 45). The mutations present in Cy1mS7luc and Cy1mS8luc reduced but did not eliminate TGF-beta -induced transcription (Fig. 2), suggesting that these mutated sequences may also contribute to the TGF-beta induction of VIP CyRE transcription. Mutations in other regions within the 3' CyRE resulted in reduced unstimulated and TGF-beta -stimulated luciferase activity but no significant alteration in the overall TGF-beta induction (Fig. 2). The exception to this, the large TGF-beta induction of Cy1mS6luc, was not reproducible. These data suggest that the sequence TCAGAC is critical to the ability of TGF-beta to induce transcription through the VIP CyRE.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 2.   Mutation of specific sequences within the 3'-end reduce the TGF-beta inducibility of the CyRE. NBFL cells, transfected with the luciferase reporter plasmids shown, were either left untreated or treated for 40 h with TGF-beta (2.5 ng/ml) before harvesting and analysis of luciferase and beta -galactosidase activity. Data are of a representative experiment performed in triplicate. Data are presented as normalized luciferase activity (mean ± S.E.) and as -fold induction in luciferase activity. The experiment was repeated three times with similar results.

We then examined the rest of the CyRE sequence to look for other regions that might have similarity to the CAGA site at the 3'-end of the CyRE. Interestingly, we found one other region, toward the center of the CyRE, that also contained the core CAGA sequence. This sequence (TCCAGACAT) is located -1250 bp upstream of the transcription start site. To determine whether Smad proteins could bind to these CAGA containing sequences from the VIP CyRE, we incubated purified GST-Smad fusion with probes from these regions, P17 and P11 (Table I). EMSA analysis indicated that GST-Smad3Delta C bound to the CAGA-containing probes, P17 and P11, and to a control SBE but not to an adjacent, non-CAGA-containing probe, P18 (Fig. 3C). Binding of GST-Smad3Delta C to either P17 or P11 was specifically competed by a 100-fold molar excess of nonlabeled wild type oligonucleotide but not by the same amount of these sequences with 3-bp mutations in their CAGA boxes (Fig. 3D). GST-Smad4 bound very weakly to either P17 or P11, despite strong binding to the control SBE (Fig. 3E). Truncated GST-Smad4Delta C, without the C-terminal MH2 domain, did not bind more strongly than full-length GST-Smad4 (data not shown), suggesting that it was not the presence of the MH2 domain that inhibited Smad4 binding to the CyRE sequences. Taken together, these data show that two sites within the VIP CyRE are able strongly and specifically to bind Smad3 but that these same sites bind Smad4 only weakly.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 3.   Smad proteins can bind to two distinct sites with in the VIP CyRE. A, schematic representation of the CyRE, showing the locations of known and putative transcription factor binding sites, together with the positions of EMSA probes. B, alignment of sequence of probes used in EMSA. C, EMSA with purified GST (G) or GST-Smad3Delta C (S3) with three different probes from the CyRE and the positive control SBE. D, EMSA with GST-Smad3Delta C binding to two probes from the CyRE. Competing oligonucleotides were present at a 100-fold molar excess. E, EMSA with purified GST-Smad fusion proteins binding to SBE, P17, and P11 probes. The arrow indicates the position of weak GST-Smad4 binding to P17 and P11.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Oligonucleotide sequences

To assess the role of these two CyRE Smad binding sites in mediating TGF-beta inducibility of CyRE-directed transcription, we examined the ability of TGF-beta to induce transcription of luciferase reporter plasmids containing mutations in either or both of these Smad sites. Identical mutations to those that eliminated the ability of Smad proteins to bind to P17 or P11 were introduced into the wild type Cy1luc plasmid. Transfection of these plasmids into NBFL cells indicated that mutation of either P17 or P11 attenuated the ability of TGF-beta to induce CyRE-mediated transcription (Fig. 4). Mutation of both P17 and P11 completely eliminated the ability of TGF-beta to induce CyRE-driven transcription. Thus, while each CyRE Smad binding site contributes, both sites are necessary to TGF-beta induction of CyRE-driven transcription.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 4.   Mutation of the CyRE Smad sites eliminates the TGF-beta inducibility of the CyRE. NBFL cells, transfected with the luciferase reporter plasmids shown, were either left untreated or treated for 40 h with TGF-beta (2.5 ng/ml) before harvesting and analysis of luciferase and beta -galactosidase activity. Data are of a representative experiment performed in triplicate (mean ± S.E.). The experiment was repeated three times with similar results.

To determine whether TGF-beta induces endogenous proteins within NBFL cells to bind to these Smad sites, we prepared nuclear extract from untreated and TGF-beta -treated NBFL cells. After 1 h of treatment, TGF-beta strongly induced NBFL nuclear protein binding to probes containing the CyRE Smad binding sequences (Fig. 5). The probe, P21, is a truncated version of P17. The TGF-beta -induced p21-binding complex is competed specifically by a 100-fold molar excess of unlabeled probe and also by a similar molar excess of P17 and P11. It is not competed by oligonucleotides with mutations in their CAGA boxes that were unable to bind GST-Smad proteins (Fig. 5A). These data suggest that in NBFL cells, TGF-beta activates Smad proteins to translocate to the nucleus and bind to Smad binding sites within the VIP CyRE. Confirmation of the composition of these TGF-beta -induced binding complexes was obtained by demonstrating that an antibody recognizing Smad2 and Smad3 was able to interfere with binding of these complexes to the P21 and P11 probes (Fig. 5). Thus, taken together, our data show that TGF-beta induces Smad proteins to bind to two sites with the VIP CyRE and that this binding is critical for TGF-beta induction of VIP transcription.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 5.   TGF-beta induces a Smad containing complex to bind to a site in the VIP CyRE. EMSAs with nuclear extract prepared from NBFL cells either untreated or treated with TGF-beta (5 ng/ml) for 1 h. Competing oligonucleotides were present at a 100-fold molar excess. 2 µg of the antiserum that recognizes Smad2 and Smad3 (Upstate Biotechnology, Inc.) was added to the nuclear extract 10 min before the addition of probe.

We first demonstrated the VIP CyRE to be a response element for the gp130 cytokines (in particular for CNTF) (35) and subsequently that CNTF synergized with activin to induce VIP mRNA (34). Since activin and TGF-beta utilize very similar pathways to regulate gene expression, we wanted to confirm that CNTF would also synergize with TGF-beta to induce VIP mRNA. Analysis of VIP mRNA expression in NBFL cells by Northern blotting showed that TGF-beta treatment alone induced VIP mRNA in a dose-dependent manner. 1 ng/ml TGF-beta induced VIP mRNA 2.8-fold, and 10 ng/ml led to a 12.4-fold induction of VIP mRNA (Fig. 6). As we had previously observed with activin, the TGF-beta induction is significantly less robust than that elicited by CNTF, which produced a 55-fold induction in VIP mRNA. When NBFL cells were treated with CNTF together with TGF-beta , VIP mRNA was markedly induced: 147-fold by CNTF with 1 ng/ml TGF-beta and 257-fold by CNTF together with 10 ng/ml TGF-beta (Fig. 6). Thus, TGF-beta acts synergistically with CNTF to induce VIP mRNA.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 6.   TGF-beta synergizes with CNTF to induce VIP mRNA expression. A, Northern blot of cytoplasmic RNA (20 µg) isolated from NBFL cells treated with TGF-beta and/or CNTF (25 ng/ml) for 48 h. B, graphical representation of data from Northern blot shown in A, quantitated on a PhosphorImager. VIP mRNA levels are normalized to those of cyclophilin mRNA and presented as a relative ratio.

TGF-beta and CNTF both induce VIP gene transcription through inducing proteins to bind to specific sequences within the VIP CyRE, yet they activate different transcription factors. We wanted to assess the contribution of sites important to either the CNTF or TGF-beta pathways to the synergistic signaling of these two independent cytokines. We therefore introduced additional mutations at the STAT and/or AP-1 sites into the Cy1luc reporter with both Smad sites mutated and compared the activity of all of these mutated luciferase reporters to the wild type Cy1luc plasmid. NBFL cells transfected with Cy1luc reproduced the synergistic effect of CNTF and TGF-beta on VIP mRNA, mediating strong inducibility by CNTF, less by TGF-beta , and very marked synergistic signaling by cotreatment with the two cytokines (Fig. 7). In cells transfected with Cy1mg17mg11 (containing mutations of both CyRE Smad sites), TGF-beta was no longer able to induce luciferase activity, as shown previously (Fig. 4). Interestingly, the CNTF-induced transcription driven by Cy1mg17mg11 was reduced by 60% in comparison with Cy1luc, and there was no significant difference in transcriptional induction after cotreatment with both cytokines from that of CNTF alone (Fig. 7). Transcriptional activity driven by a luciferase reporter with mutations in both Smad sites and the AP-1 site (Cy1mg17mg11mg2) was not induced by TGF-beta but still retained CNTF induction. The synergy between TGF-beta and CNTF was no longer evident. Plasmids containing mutations of the Smad and STAT sites (Cy1mg17mg11mg3) or of the Smad, STAT, and AP-1 sites (Cy1mg17mg11mg3mg2) did not respond to stimulation by either cytokine alone or together. These data suggest that CNTF and TGF-beta synergistically induce CyRE transcription through stimulating a combination of Smad, STAT, and AP-1 proteins.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 7.   Synergistic signaling of TGF-beta and CNTF requires the Smad, STAT, and AP-1 sites. NBFL cells, transfected with the luciferase reporter plasmids shown, were either left untreated or treated for 40 h with TGF-beta (2.5 ng/ml) and/or CNTF (25 ng/ml) before harvesting and analysis of luciferase and beta -galactosidase activity. Data are presented as -fold induction of luciferase activity normalized to beta -galactosidase activity (mean ± S.E.) of three independent experiments.

CNTF and TGF-beta stimulate very different signaling pathways to activate gene expression. However, the possibility of cross-talk between these pathways exists at many different levels. Smad proteins, while initially phosphorylated by the receptor, may also be phosphorylated by cytoplasmic kinases, such as the extracellular signal-regulated kinases (37, 46). To investigate whether CNTF signaling may contribute to Smad activation, independent of any potential Smad-DNA binding effects, we utilized Gal4-Smad fusion proteins. Expression vectors for Gal4-Smad fusion proteins were co-transfected with a reporter containing multimerized Gal4 DNA binding sites, pG5-E1B-luc. As previously published (37, 47), TGF-beta induced transcriptional activation mediated by Gal4-Smad2, Gal4-Smad3, and Gal4-Smad4 but not by Gal4 alone (Fig. 8A). TGF-beta induction of Gal4-Smad3 transcriptional activity was the most robust. CNTF did not induce transcription by any Gal4-Smad fusion proteins. However, CNTF and TGF-beta co-treatment significantly induced Gal4-Smad3-mediated transcription over that of TGF-beta alone. While there was a trend toward this difference with Gal4-Smad2 and Gal4-Smad4, this trend was not significant. These data suggest that while CNTF signals alone do not induce Smad transcriptional activation, CNTF may enhance TGF-beta 's activation of Smad3. However, CNTF and TGF-beta co-treatment did not enhance TGF-beta 's induction of the multimerized SBE luciferase reporter, SBE luc (Fig. 8D). These data suggest that CNTF does not significantly alter the TGF-beta activation of endogenous Smad proteins. Thus, the effects of CNTF signals on TGF-beta induction of Smad transcriptional activity are minimal.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 8.   CNTF and TGF-beta signal through independent pathways. NBFL cells were transfected as shown and were left untreated or treated for 40 h with TGF-beta (2.5 ng/ml) and/or CNTF (25 ng/ml) before harvesting and analysis of luciferase and beta -galactosidase activity. A, NBFL cells were transfected with expression plasmids for the Gal4-Smad fusion plasmids together with the Gal4 reporter plasmid, pG5-E1B-luc, containing five copies of the Gal4 DNA binding site. Data are from a representative experiment performed in triplicate (mean ± S.E.) The experiment was repeated four times with similar results. Data were analyzed by one way analysis of variance and evaluated using the Bonferroni multiple comparisons test. Significant differences between normalized luciferase activity in lysates from untreated cells and those in lysates from cytokine-treated cells within each group are indicated: *, p < 0.05; **, p < 0.01; ***, p < 0.001. Additionally, there is a significant difference (p < 0.001) in the normalized luciferase activity from Gal4-Smad3-transfected cells, between those treated with TGF-beta and those with CNTF plus TGF-beta . B, C, and D, NBFL cells were transfected with the luciferase reporter plasmids shown. Experiments were repeated a minimum of twice with similar results.

To determine whether TGF-beta may affect CNTF activated pathways, we examined the effects of cytokine cotreatment on luciferase reporters driven by multimerized STAT (G3) or AP-1 (G2) sites. We have previously shown that CNTF does not induce transcription driven by multimerized AP-1 sites and only minimally induces transcription driven by a multimerized VIP-STAT site, 3×G3 luc (here 2-fold; Fig. 8C) (20, 35). TGF-beta treatment did not induce transcription driven by either multimerized STAT or AP-1 sites and in fact inhibited the basal levels of transcription of these plasmids. This effect was partially due to a slight stimulation by TGF-beta of the co-transfected normalization plasmid, EF-beta -galactosidase (data not shown). TGF-beta did not alter the CNTF induction of STAT-mediated transcription, nor did it induce transcription driven by the multimerized AP-1 site (3×G2-luc). Thus, TGF-beta signals do not alter the CNTF-stimulated pathways we have examined. Our data suggest that CNTF and TGF-beta independently activate distinct signal pathways, leading to the stimulation of specific transcription factors that bind to consensus sites on the VIP CyRE.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The VIP CyRE is able to mediate independent and synergistic signaling by the gp130 and TGF-beta family of cytokines. This 180-bp sequence is able to respond to these two distinct classes of cytokines because it contains within it consensus sequences for transcription factors that are rapidly activated by cytokine signaling. Hence, CNTF induces STAT and AP-1 proteins to bind to their specific sites within the CyRE, and TGF-beta induces Smad proteins to bind to Smad sites also contained in the CyRE. The information encoded within the VIP CyRE therefore allows signaling by these cytokine classes to interact by the cooperation of transcription factors binding to DNA within a relatively small region.

We have shown that a C-terminal truncated Smad3 protein can bind to two distinct sites within the VIP CyRE (Fig. 3). Mutation of both of these sites abolishes the ability of TGF-beta to induce transcription through the VIP CyRE (Fig. 4). Both Smad sequences have strong homology to Smad binding sites in many other genes including the PAI and junB promoters (45, 48). From EMSA studies it appears that the sequence within P17, CCAGACA, has higher affinity for GST-Smad3Delta C than the sequence within P11, TCAGACT (data not shown). Additionally, we have shown that in NBFL cells TGF-beta induces nuclear protein complexes to bind to these two Smad sites within the CyRE. These complexes are removed by antiserum recognizing both Smad2 and Smad3 (Fig. 5). Smad2 does not bind to DNA (49), so these binding complexes probably contain Smad3. However, we cannot rule out the involvement of Smad2 in transcriptional activation of the VIP gene by TGF-beta . GST-Smad4 can bind weakly to the two CyRE Smad sites. Although Smad4 can bind to sites with a CAGA box (39), it also has shown preference for a GC-rich site, similar to that to which the Drosophila Smad homolog Mad binds in the promoter of the vestigial gene (24). Our results indicate a discrepancy between the affinity of Smad3 and Smad4 for the VIP CyRE Smad sites, suggesting that Smad3 and Smad4 proteins have different sequence specificity even within binding to CAGA box sites. Removing the C-terminal MH2 domain from Smad4 did not increase binding to the CyRE Smad sites, in contrast to the results of Jonk et al. (48), who show much improved binding of GST-Smad4Delta C over full-length GST-Smad4 to sites in the JunB promoter. Thus, Smad4 may require other proteins to assist its binding to the VIP CyRE.

Smad proteins bind DNA with low affinity (49). Therefore, to achieve high affinity interaction with specific DNA sequences, Smad proteins usually form complexes with other transcriptional co-factors or bind as multimeric proteins to repeats of the CAGA motif (50, 51). Cooperative binding of Smad proteins confers a greater level of specificity, conferring dependence on the specific promoter sequence of each gene and the availability of co-factors with which to bind. The distance between the two VIP CyRE Smad sites (85 bp) suggests that Smad proteins require other proteins to achieve high affinity binding. Thus, Smad3, possibly together with Smad2 and Smad4, may bind to each site in complex with an as yet unknown transcriptional co-factor. Indeed, in EMSA experiments, we have seen a larger TGF-beta -induced nuclear protein complex binding to the longer P17 probe than binds to P21 (data not shown). However, our data also show that deleting or mutating only one Smad site significantly reduces the ability of TGF-beta to induce transcription through the VIP CyRE (Figs. 1 and 4). Thus, one Smad site alone together with its adjacent sequence is not sufficient to confer full TGF-beta induction of VIP transcription. The two Smad sites may functionally cooperate through the looping out of intervening sequences to form a greater transcriptional activating complex with which to recruit co-activators.

While the Smad sites within the VIP CyRE are critical for TGF-beta -mediated induction of CyRE transcriptional activity, the AP-1 site is an additional site through which TGF-beta may act. We have previously shown that mutation of the AP-1 site in the VIP CyRE reduces activin-mediated induction of CyRE-directed transcription ~50% (34). However, our observation that mutation of the CyRE Smad sites eliminated TGF-beta stimulation of CyRE transcription suggests that the Smad sites are more critical to the CyRE response to TGF-beta than the AP-1 site. Our data are in contrast to studies on the collagenase promoter, where mutations in the AP-1 site within the collagenase I promoter reduce TGF-beta -mediated induction of this gene to a much greater extent than mutations in any or all of the Smad sites (52). Thus, the relative contributions of the AP-1 and Smad sites to transcriptional induction by TGF-beta appear to be gene-specific.

One possible mechanism mediating the synergy between CNTF and TGF-beta is the convergence of their signaling pathways to activate specific transcription factors. Our data suggest that some kinase activation by CNTF may contribute to Smad transcriptional activation when already activated by TGF-beta (Fig. 8A). However, this effect is likely to be minimal due to the lack of synergistic signaling by CNTF and TGF-beta in the activation of a transcriptional reporter composed of multimerized Smad sites (Fig. 8D). Thus, synergy between CNTF and TGF-beta is not mediated solely through Smad proteins; nor can TGF-beta synergize with CNTF in activation of a multimerized STAT reporter. Thus, the synergy between CNTF and TGF-beta is not mediated by the action of one cytokine signaling directly to the transcription factor activated by the second cytokine.

CNTF and TGF-beta activate pathway-specific transcription factors that translocate to the nucleus to activate gene transcription through the VIP CyRE. As STAT, Smad, and AP-1 sites contribute to the synergistic signaling by these independent cytokines, it seems possible that these activated transcription factors are able to form a more stable transcriptional activation complex when activated together than when either pathway alone is activated. Such a transcriptional activation complex would provide a base for interaction with co-activators such as CBP/p300. As Smad, AP-1, and STAT proteins all interact directly with CBP (53-56), CBP may act as a bridging molecule to mediate the synergy between these pathways. Indeed, CBP/p300 is implicated in the synergistic interaction between BMP2 and LIF induction of the GFAP promotor in fetal neuroepithelial cells through bridging LIF-induced STAT3 with the BMP2-induced Smad1 (57). Thus, we hypothesize that transcription factors activated by both cytokine signaling pathways act together with constitutive and cell-specific transcription factors to form a more stable surface with which to recruit co-activators.

CNTF and TGF-beta together with their related cytokines have important roles in neuronal survival, development, and mediation of some of the responses of the nervous system to injury (32, 58). Neuronal and nonneuronal cells within the nervous system can respond to cytokines of both families dependent on the specific receptors expressed. Each cytokine acts in cooperation with its environment. Thus, it is important to understand the molecular details through which specific cytokines interact to influence cellular functions. Gp130 cytokines may interact with certain members of the TGF-beta cytokine family in the glial reaction to injury, in astrocyte differentiation, and in neuronal survival. Indeed, BMP2 and LIF synergize in the development of astrocytes (57) from neuroepithelial cells, and CNTF and TGF-beta cooperate to mediate the survival of chick ciliary ganglion neurons (33). The regulation of VIP gene expression is another example of functional cooperation between these two cytokine families. TGF-beta is generally considered a modulator cytokine, having different effects dependent on the cellular context. Thus, its ability to synergize with CNTF allows target cells enhanced ability to regulate their responses to low doses of cytokines. Such combinatorial action increases the repertoire of options available to the cell and makes them more finely tuned to the environmental cytokine milieu.

    ACKNOWLEDGEMENTS

We thank Fern Murdoch and Bob Lechleider and members of their laboratories for many helpful discussions and suggestions. We also gratefully acknowledge assistance and suggestions from Liliana Attisiano. We thank Regeneron Pharmaceuticals for supplying the CNTF.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant R29 NS-35839 and Uniformed Services University of the Health Sciences intramural support (to A. J. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Dept. of Pharmacology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD 20814. Tel.: 301-295-3234; Fax: 301-295-3220; E-mail: Asymes@usuhs.mil.

Published, JBC Papers in Press, March 20, 2001, DOI 10.1074/jbc.M011759200

    ABBREVIATIONS

The abbreviations used are: TGF, transforming growth factor; CNTF, ciliary neurotrophic factor; LIF, leukemia inhibitory factor; Tbeta R-I and -II, TGF-beta type I and II receptor, respectively; CyRE, cytokine response element; STAT, signal transducers and activators of transcription; bp, base pair(s); EMSA, electrophoretic mobility shift assay; GST, glutathione S-transferase; VIP, vasoactive intestinal peptide; SBE, Smad-binding element.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Ip, N. Y., Nye, S. H., Boulton, T. G., Davis, S., Taga, T., Li, Y., Birren, S. J., Yasukawa, K., Kishimoto, T., Anderson, D. J., Stahl, N., and Yancopoulos, G. D. (1992) Cell 69, 1121-1132[Medline] [Order article via Infotrieve]
2. Davis, S., Aldrich, T. H., Stahl, N., Pan, L., Taga, T., Kishimoto, T., Ip, N. Y., and Yancopoulos, G. D. (1993) Science 260, 1805-1808[Medline] [Order article via Infotrieve]
3. De Serio, A., Graziani, R., Laufer, R., Ciliberto, G., and Paonessa, G. (1995) J. Mol. Biol. 254, 795-800[CrossRef][Medline] [Order article via Infotrieve]
4. Carpenter, L. R., Yancopoulos, G. D., and Stahl, N. (1998) Adv. Protein Chem. 52, 109-140[Medline] [Order article via Infotrieve]
5. Guschin, D., Rogers, N., Briscoe, J., Witthun, B., Watling, D., Horn, F., Pellegrini, S., Yasukawa, K., Heinrich, P., Stark, G., Ihle, J., and Kerr, I. (1995) EMBO J. 1421-1429
6. Narazaki, M., Witthuhn, B. A., Yoshida, K., Silvennoinen, O., Yasukawa, K., Ihle, J. N., Kishimoto, T., and Taga, T. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2285-2289[Abstract]
7. Stahl, N., Boulton, T. G., Farruggella, T., Ip, N. Y., Davis, S., Witthuhn, B. A., Quelle, F. W., Silvennoinen, O., Barbieri, G., Pellegrini, S., Inle, J. N., and Yancopoulos, G. D. (1994) Science 263, 92-95[Medline] [Order article via Infotrieve]
8. Stahl, N., Farruggella, T. J., Boulton, T., Zhong, Z., Darnell, J., and Yancopoulos, G. D. (1995) Science 267, 1349-1353[Medline] [Order article via Infotrieve]
9. Stahl, N., and Yancopoulos, G. D. (1994) J. Neurobiol. 25, 1454-1466[Medline] [Order article via Infotrieve]
10. Bonni, A., Frank, D. A., Schindler, C., and Greenberg, M. E. (1993) Science 262, 1575-1579[Medline] [Order article via Infotrieve]
11. Lutticken, C., Wegenka, U. M., Yuan, J., Buschmann, J., Schindler, C., Ziemiecki, A., Harpur, A. G., Wilks, A. F., Yasukawa, K., Taga, T., Kishimoto, T., Barbieri, G., Pellegrini, S., Sendtner, M., Heinrich, P. C., and Horn, F. (1994) Science 263, 89-92[Medline] [Order article via Infotrieve]
12. Zhong, Z., Wen, Z., and Darnell, J. E. J. (1994) Science 264, 95-98[Medline] [Order article via Infotrieve]
13. Heinrich, P. C., Behrmann, I., Muller-Newen, G., Schaper, F., and Graeve, L. (1998) Biochem. J. 334, 297-314[Medline] [Order article via Infotrieve]
14. Schwarzschild, M. A., Dauer, W. T., Lewis, S. E., Hamill, L. K., Fink, J. S., and Hyman, S. E. (1994) J. Neurochem. 63, 1246-1254[Medline] [Order article via Infotrieve]
15. Boulton, T. G., Stahl, N., and Yancopoulos, G. D. (1994) J. Biol. Chem. 269, 11648-11655[Abstract/Free Full Text]
16. Schiemann, W. P., and Nathanson, N. M. (1994) J. Biol. Chem. 269, 6376-6382[Abstract/Free Full Text]
17. Giordano, V., De Falco, G., Chiari, R., Quinto, I., Pelicci, P. G., Bartholomew, L., Delmastro, P., Gadina, M., and Scala, G. (1997) J. Immunol. 158, 4097-4103[Abstract]
18. Schiemann, W. P., Bartoe, J. L., and Nathanson, N. M. (1997) J. Biol. Chem. 272, 16631-16636[Abstract/Free Full Text]
19. Chen, R. H., Chang, M. C., Su, Y. H., Tsai, Y. T., and Kuo, M. L. (1999) J. Biol. Chem. 274, 23013-23019[Abstract/Free Full Text]
20. Symes, A. J., Gearan, T., Eby, J., and Fink, J. S. (1997) J. Biol. Chem. 272, 9648-9654[Abstract/Free Full Text]
21. Wang, Y., and Fuller, G. M. (1995) Gene (Amst.) 162, 285-289[CrossRef][Medline] [Order article via Infotrieve]
22. Massague, J., and Wotton, D. (2000) EMBO J. 19, 1745-1754[Abstract/Free Full Text]
23. Miyazono, K., ten Duke, P., and Heldin, C. H. (2000) Adv. Immunol. 75, 115-157[Medline] [Order article via Infotrieve]
24. Kim, J., Johnson, K., Chen, H. J., Carroll, S., and Laughon, A. (1997) Nature 388, 304-308[CrossRef][Medline] [Order article via Infotrieve]
25. Derynck, R., Zhang, Y., and Feng, X. H. (1998) Cell 95, 737-740[Medline] [Order article via Infotrieve]
26. Blottner, D., Wolf, N., Lachmund, A., Flanders, K. C., and Unsicker, K. (1996) Eur. J. Neurosci. 8, 202-210[Medline] [Order article via Infotrieve]
27. Ren, R. F., and Flanders, K. C. (1996) Brain Res. 732, 16-24[CrossRef][Medline] [Order article via Infotrieve]
28. Krieglstein, K., Reuss, B., Maysinger, D., and Unsicker, K. (1998) Eur. J. Neurosci. 10, 2746-2750[CrossRef][Medline] [Order article via Infotrieve]
29. Poulsen, K. T., Armanini, M. P., Klein, R. D., Hynes, M. A., Phillips, H. S., and Rosenthal, A. (1994) Neuron 13, 1245-1252[Medline] [Order article via Infotrieve]
30. Magal, E., Louis, J. C., Oudega, M., and Varon, S. (1993) Neuroreport 4, 779-782[Medline] [Order article via Infotrieve]
31. Sendtner, M., Arakawa, Y., Stockli, K. A., Kreutzberg, G. W., and Thoenen, H. (1991) J. Cell Sci. (Suppl.) 15, 103-109[Medline] [Order article via Infotrieve]
32. Richardson, P. M. (1994) Pharmacol. Ther. 63, 187-198[Medline] [Order article via Infotrieve]
33. Krieglstein, K., Farkas, L., and Unsicker, K. (1998) J. Neurobiol. 37, 563-572[CrossRef][Medline] [Order article via Infotrieve]
34. Symes, A. J., Pitts, R. L., Conover, J., Kos, K., and Coulombe, J. (2000) Mol. Endocrinol. 14, 429-439[Abstract/Free Full Text]
35. Symes, A. J., Lewis, S. E., Corpus, L., Rajan, P., Hyman, S. E., and Fink, J. S. (1994) Mol. Endocrinol. 8, 1750-1763[Abstract]
36. Jones, E. A., Conover, J., and Symes, A. J. (2000) J. Biol. Chem. 275, 36013-36020[Abstract/Free Full Text]
37. de Caestecker, M. P., Parks, W. T., Frank, C. J., Castagnino, P., Bottaro, D. P., Roberts, A. B., and Lechleider, R. J. (1998) Genes Dev. 12, 1587-1592[Abstract/Free Full Text]
38. Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease, L. R. (1989) Gene (Amst.) 77, 51-59[CrossRef][Medline] [Order article via Infotrieve]
39. Zawel, L., Dai, J. L., Buckhaults, P., Zhou, S., Kinzler, K. W., Vogelstein, B., and Kern, S. E. (1998) Mol. Cell 1, 611-617[Medline] [Order article via Infotrieve]
40. Symes, A. J., Rao, M. S., Lewis, S. E., Landis, S. C., Hyman, S. E., and Fink, J. S. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 572-576[Abstract]
41. Brasier, A. R., Tate, J. E., and Habener, J. F. (1989) BioTechniques 7, 1116-1122[Medline] [Order article via Infotrieve]
42. Symes, A. J., Rajan, P., Corpus, L., and Fink, J. S. (1995) J. Biol. Chem. 270, 8068-8075[Abstract/Free Full Text]
43. Tsukada, T., Horovitch, S. J., Montminy, M., Mandel, G., and Goodman, R. H. (1985) DNA 4, 293-300[Medline] [Order article via Infotrieve]
44. Danielson, P. E., Forss-Petter, S., Brow, M. A., Cavaletta, L., Douglass, J., Milner, R. J., and Sutcliffe, J. G. (1988) DNA 7, 261-267[Medline] [Order article via Infotrieve]
45. Dennler, S., Itoh, S., Vivien, D., ten Dijke, P., Huet, S., and Gauthier, J. M. (1998) EMBO J. 17, 3091-3100[Abstract/Free Full Text]
46. Kretzschmar, M., Doody, J., Timokhina, I., and Massague, J. (1999) Genes Dev. 13, 804-816[Abstract/Free Full Text]
47. de Caestecker, M. P., Yahata, T., Wang, D., Parks, W. T., Huang, S., Hill, C. S., Shioda, T., Roberts, A. B., and Lechleider, R. J. (2000) J. Biol. Chem. 275, 2115-2122[Abstract/Free Full Text]
48. Jonk, L. J., Itoh, S., Heldin, C. H., ten Dijke, P., and Kruijer, W. (1998) J. Biol. Chem. 273, 21145-21152[Abstract/Free Full Text]
49. Shi, Y., Wang, Y. F., Jayaraman, L., Yang, H., Massague, J., and Pavletich, N. P. (1998) Cell 94, 585-594[Medline] [Order article via Infotrieve]
50. Johnson, K., Kirkpatrick, H., Comer, A., Hoffmann, F. M., and Laughon, A. (1999) J. Biol. Chem. 274, 20709-20716[Abstract/Free Full Text]
51. Attisano, L., and Wrana, J. L. (2000) Curr. Opin. Cell Biol. 12, 235-243[CrossRef][Medline] [Order article via Infotrieve]
52. Qing, J., Zhang, Y., and Derynck, R. (2000) J. Biol. Chem. 275, 38802-38812[Abstract/Free Full Text]
53. Bannister, A. J., and Kouzarides, T. (1995) EMBO J. 14, 4758-4762[Abstract]
54. Feng, X. H., Zhang, Y., Wu, R. Y., and Derynck, R. (1998) Genes Dev. 12, 2153-2163[Abstract/Free Full Text]
55. Horvai, A. E., Xu, L., Korzus, E., Brard, G., Kalafus, D., Mullen, T. M., Rose, D. W., Rosenfeld, M. G., and Glass, C. K. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 1074-1079[Abstract/Free Full Text]
56. Janknecht, R., Wells, N. J., and Hunter, T. (1998) Genes Dev. 12, 2114-2119[Abstract/Free Full Text]
57. Nakashima, K., Yanagisawa, M., Arakawa, H., Kimura, N., Hisatsune, T., Kawabata, M., Miyazono, K., and Taga, T. (1999) Science 284, 479-482[Abstract/Free Full Text]
58. Bottner, M., Krieglstein, K., and Unsicker, K. (2000) J. Neurochem. 75, 2227-2240[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.